When Immune System and Herpes Virus Infection Collide: A Case of Severe Stromal Herpetic Keratitis in a Patient with Rheumatoid Arthritis Under Methotrexate.

IF 0.7 Q3 MEDICINE, GENERAL & INTERNAL
International Medical Case Reports Journal Pub Date : 2026-09-05 eCollection Date: 2026-01-01 DOI:10.2147/IMCRJ.S632102
Claudia Corda, Filippo Lixi, Antonio Budroni, Mara-Ioana Tomi, Alina-Gabriela Gheorghe, Giuseppe Giannaccare
{"title":"When Immune System and Herpes Virus Infection Collide: A Case of Severe Stromal Herpetic Keratitis in a Patient with Rheumatoid Arthritis Under Methotrexate.","authors":"Claudia Corda, Filippo Lixi, Antonio Budroni, Mara-Ioana Tomi, Alina-Gabriela Gheorghe, Giuseppe Giannaccare","doi":"10.2147/IMCRJ.S632102","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To report a case of refractory herpes simplex virus keratitis (HSVK) complicated by keratolysis and severe stromal thinning in a patient with rheumatoid arthritis (RA) under treatment with methotrexate (MTX).</p><p><strong>Observations: </strong>A 79‑year‑old patient with a history of HSVK and RA, treated with weekly MTX, presented with pain and photophobia in the right eye. Best‑corrected visual acuity (BCVA) was limited to counting fingers. Slit‑lamp examination revealed a supero-nasal corneal ulcer (area of 2.98 mm<sup>2</sup>) with deep stromal involvement and keratolysis. A recurrent episode of HSVK was diagnosed, and treatment with 3 times daily oral acyclovir, 4 times daily 0.15% ganciclovir ophthalmic gel, and 3 times daily 0.15% topical dexamethasone was started. After one week, the picture worsened with corneal thinning (corneal thinnest point [CTP] 82 µm) and anterior chamber fibrin. Cycloplegic therapy 3 times daily was added. Considering the refractory course, the history of recurrent HSVK, and the concomitant systemic immunomodulation, the MTX injection scheduled for the subsequent weeks was interrupted. After 2 weeks, conjunctival hyperemia improved (Efron grade II) and a progressive increase of corneal thickness (CTP 199 µm) was documented. Two months later, complete healing was achieved with no signs of active inflammation or recurrence; BCVA improved to 0.4 LogMAR, with mild residual stromal thinning and opacity (CTP 231 µm).</p><p><strong>Conclusion and importance: </strong>This case underscores how systemic immunomodulatory treatment may play a clinically relevant role in patients with recurrent HSVK. In selected cases, a conservative, surgery‑sparing approach through the optimization of systemic therapy can help promoting viral load control and corneal healing.</p>","PeriodicalId":14337,"journal":{"name":"International Medical Case Reports Journal","volume":"19 ","pages":"632102"},"PeriodicalIF":0.7000,"publicationDate":"2026-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13557219/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Medical Case Reports Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/IMCRJ.S632102","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To report a case of refractory herpes simplex virus keratitis (HSVK) complicated by keratolysis and severe stromal thinning in a patient with rheumatoid arthritis (RA) under treatment with methotrexate (MTX).

Observations: A 79‑year‑old patient with a history of HSVK and RA, treated with weekly MTX, presented with pain and photophobia in the right eye. Best‑corrected visual acuity (BCVA) was limited to counting fingers. Slit‑lamp examination revealed a supero-nasal corneal ulcer (area of 2.98 mm2) with deep stromal involvement and keratolysis. A recurrent episode of HSVK was diagnosed, and treatment with 3 times daily oral acyclovir, 4 times daily 0.15% ganciclovir ophthalmic gel, and 3 times daily 0.15% topical dexamethasone was started. After one week, the picture worsened with corneal thinning (corneal thinnest point [CTP] 82 µm) and anterior chamber fibrin. Cycloplegic therapy 3 times daily was added. Considering the refractory course, the history of recurrent HSVK, and the concomitant systemic immunomodulation, the MTX injection scheduled for the subsequent weeks was interrupted. After 2 weeks, conjunctival hyperemia improved (Efron grade II) and a progressive increase of corneal thickness (CTP 199 µm) was documented. Two months later, complete healing was achieved with no signs of active inflammation or recurrence; BCVA improved to 0.4 LogMAR, with mild residual stromal thinning and opacity (CTP 231 µm).

Conclusion and importance: This case underscores how systemic immunomodulatory treatment may play a clinically relevant role in patients with recurrent HSVK. In selected cases, a conservative, surgery‑sparing approach through the optimization of systemic therapy can help promoting viral load control and corneal healing.

当免疫系统和疱疹病毒感染碰撞:甲氨蝶呤治疗类风湿关节炎患者发生严重间质疱疹性角膜炎1例。
目的:报告一例难治性单纯疱疹病毒角膜炎(HSVK)合并角化和严重间质变薄的类风湿关节炎(RA)患者在接受甲氨蝶呤(MTX)治疗。观察:79岁患者,有HSVK和RA病史,每周接受甲氨蝶呤治疗,表现为右眼疼痛和畏光。最佳矫正视力(BCVA)仅限于数手指。裂隙灯检查显示上鼻角膜溃疡(面积2.98 mm2),伴有深部间质受累和角化。诊断为HSVK复发,开始每日3次口服阿昔洛韦,每日4次0.15%更昔洛韦眼用凝胶,每日3次0.15%外用地塞米松治疗。一周后,视力恶化,角膜变薄(角膜最薄点[CTP] 82µm),前房纤维蛋白增多。每日增加3次单眼麻痹治疗。考虑到患者的难治性病程、HSVK复发史以及伴随的全身免疫调节,原定于随后几周的甲氨蝶呤注射被中断。2周后,结膜充血得到改善(efr2级),角膜厚度逐渐增加(CTP 199µm)。两个月后,完全愈合,无活动性炎症或复发迹象;BCVA改善至0.4 LogMAR,残余基质轻度变薄和不透明(CTP 231µm)。结论和重要性:该病例强调了系统性免疫调节治疗在复发性HSVK患者中可能发挥的临床相关作用。在选定的病例中,通过优化全身治疗的保守、免手术方法可以帮助促进病毒载量控制和角膜愈合。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Medical Case Reports Journal
International Medical Case Reports Journal MEDICINE, GENERAL & INTERNAL-
CiteScore
1.40
自引率
0.00%
发文量
135
审稿时长
16 weeks
期刊介绍: International Medical Case Reports Journal is an international, peer-reviewed, open access, online journal publishing original case reports from all medical specialties. Submissions should not normally exceed 3,000 words or 4 published pages including figures, diagrams and references. As of 1st April 2019, the International Medical Case Reports Journal will no longer consider meta-analyses for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书